>
pdufa.bio

Monalizumab

Updated ยทnext FDA decision on the calendar

Monalizumab is a Innate Pharma SA program. Its next catalyst is a Readout in Mar 2027. Every date links its source.

IPHA catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Innate Pharma SA (IPHA). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Mar 2027IPHA

Questions

When is Monalizumab's next FDA decision or readout?

The next tracked catalyst for Monalizumab is a Readout in Mar 2027.

What happened at Monalizumab's most recent FDA decision?

No FDA decision for Monalizumab is in our archive yet.

Who makes Monalizumab?

Innate Pharma SA (IPHA).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.